Sam Chun Dang Pharm Co Ltd banner
S

Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250

Watchlist Manager
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Watchlist
Price: 403 000 KRW -15.25%
Market Cap: ₩9.5T

Sam Chun Dang Pharm Co Ltd
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sam Chun Dang Pharm Co Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Common Stock
₩11.7B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
1%
Yuhan Corp
KRX:000100
Common Stock
₩81.4B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
4%
SK Biopharmaceuticals Co Ltd
KRX:326030
Common Stock
₩39.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Common Stock
₩32B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
2%
M
Mezzion Pharma Co Ltd
KOSDAQ:140410
Common Stock
₩15.2B
CAGR 3-Years
4%
CAGR 5-Years
28%
CAGR 10-Years
14%
C
Caregen Co Ltd
KOSDAQ:214370
Common Stock
₩5.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
No Stocks Found

Sam Chun Dang Pharm Co Ltd
Glance View

Market Cap
9.5T KRW
Industry
Pharmaceuticals

Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets. The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.

Intrinsic Value
8 992.31 KRW
Overvaluation 98%
Intrinsic Value
Price ₩403 000
S

See Also

What is Sam Chun Dang Pharm Co Ltd's Common Stock?
Common Stock
11.7B KRW

Based on the financial report for Dec 31, 2025, Sam Chun Dang Pharm Co Ltd's Common Stock amounts to 11.7B KRW.

What is Sam Chun Dang Pharm Co Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
1%

Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Sam Chun Dang Pharm Co Ltd have been 1% over the past three years , 1% over the past five years , and 1% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett